ArticleCell death & disease2025
De-ubiquitinase USP35 promotes peritoneal dissemination of gastric cancer by regulating metabolic reprogramming.
Article in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Decoding the PTM code of cGAS-STING in gastric cancer: from innate DNA sensing to precision combination therapy.Frontiers in immunology · 2026Review
- Exosome-orchestrated network in gastric cancer: mechanisms, immune regulation, biomarkers and therapeutic vehicles.Frontiers in cell and developmental biology · 2026Review
- Regulatory roles of five key USP family deubiquitinases in cancer: from mechanisms to targeted therapy advances.Frontiers in pharmacology · 2026Review
- Glycolytic Reprogramming Mediated by the OTUD4-FXR1-HIF1A Axis Drives Gastric Cancer Progression.International journal of biological sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
The enhanced adhesion between gastric cancer (GC) cells and peritoneal mesothelial cells (PMCs) is one of the key factors in the formation of the pre-peritoneal-metastasis adaptive microenvironment. USP35 belongs to the ubiquitin-specific protease family and is involved in regulating the occurrence and progression of various diseases. However, whether this gene can regulate the adhesion of GC cells to PMCs has not been clarified. The aim of this study was to identify the mechanism by which USP35 promotes the formation of the pre-peritoneal-metastasis adaptive microenvironment of GC and to find potential therapeutic targets. For the first time, we found that USP35 expression is upregulated in GC tissues, especially in peritoneal metastatic nodules, and is associated with poor prognosis. USP35 expression is the highest in MKN-45P, which is closely related to its high peritoneal metastasis potential. The mechanism of action involves several key steps. Firstly, the gene targets STING through de-ubiquitination and stabilizes its expression. Through this interaction, USP35/STING activates the HIF-1α/FAK pathway, promoting energy metabolism reprogramming and further improving the adhesion ability of GC cells. Secondly, exosome USP35 derived from GC cells has been shown to promote the mesothelial-mesenchymal transformation (MMT) of PMCs, preparing the "soil" for cancer cell adhesion and growth and contributing to the establishment of a pre-peritoneal-metastasis adaptive microenvironment. In summary, USP35 synergistically promotes the establishment of this environment through the dual mechanisms of regulating energy metabolic reprogramming of tumor cells and inducing the MMT of PMCs via the exosome pathway, providing a new theoretical basis for searching for therapeutic targets of gastric cancer with peritoneal dissemination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.